Javascript must be enabled to continue!
Abstract P6-12-03: Development of technology for bi-directional, tailored support of the relationship between breast cancer patients and their providers
View through CrossRef
Abstract
Background: It has been repeatedly recognized that current electronic medical record (EMR) systems detract from the patient-provider relationship and that innovative technology is needed to re-center medical encounters on the patient-provider relationship. This is especially important during breast cancer diagnosis and treatment.Methods: We interviewed breast cancer patients and their providers to understand the needs of each. Perspectives from both patients and providers were recorded and collated through discussions and subsequent field pilot tests which we used to validate and prioritize features or functions needed in the app to support each side of the medical encounter. Results: Patients reported wanting a system that centrally housed their diagnostic and treatment related information. They wanted the ability to share information with their caregivers (family and friends) as well as report symptoms (patient reported outcomes - PROs) to their providers. Providers reported wanting a way to gather and use PROs to intervene as soon as possible on the symptoms reported by the patients that might cause treatment delays or decrease adherence to the treatment regimen. Providers also wanted a way to easily consume the patient’s breast cancer journey and understand the current status of the patient. Using the interviews, we collated a set of the most critical capabilities and created a bi-directional mobile portal for patients and providers that has a tailored interface for each role. The resulting platform enables breast cancer patients to record their diagnosis, track appointments, and store PROs. In addition, patients can invite caregivers to the platform to view their medical history and help them in their care journey. Patients can also share their information with their providers. The provider side of the mobile app allows the doctor to view the patient’s longitudinal case summary as well as any PROs, manage patient encounters and includes a chat function for the patient’s medical team to communicate with each other regarding the patient’s case. Conclusion: We demonstrate that it is possible to build and deploy a mobile application to support patient-provider engagement. We show initial results that are promising for a bi-directional platform that reduces friction in patient-provider engagement.
Citation Format: Sharon Hensley Alford, Rohit Mahatma, Sagar Amode, Rupal Sethia, Kartik Mahatma, Hitesh Mahatma, Varun Mahatma, Nayan Sonawane, Shilpa Mahatma, Tarun Kumar, Kanchan Chawala. Development of technology for bi-directional, tailored support of the relationship between breast cancer patients and their providers [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-12-03.
American Association for Cancer Research (AACR)
Title: Abstract P6-12-03: Development of technology for bi-directional, tailored support of the relationship between breast cancer patients and their providers
Description:
Abstract
Background: It has been repeatedly recognized that current electronic medical record (EMR) systems detract from the patient-provider relationship and that innovative technology is needed to re-center medical encounters on the patient-provider relationship.
This is especially important during breast cancer diagnosis and treatment.
Methods: We interviewed breast cancer patients and their providers to understand the needs of each.
Perspectives from both patients and providers were recorded and collated through discussions and subsequent field pilot tests which we used to validate and prioritize features or functions needed in the app to support each side of the medical encounter.
Results: Patients reported wanting a system that centrally housed their diagnostic and treatment related information.
They wanted the ability to share information with their caregivers (family and friends) as well as report symptoms (patient reported outcomes - PROs) to their providers.
Providers reported wanting a way to gather and use PROs to intervene as soon as possible on the symptoms reported by the patients that might cause treatment delays or decrease adherence to the treatment regimen.
Providers also wanted a way to easily consume the patient’s breast cancer journey and understand the current status of the patient.
Using the interviews, we collated a set of the most critical capabilities and created a bi-directional mobile portal for patients and providers that has a tailored interface for each role.
The resulting platform enables breast cancer patients to record their diagnosis, track appointments, and store PROs.
In addition, patients can invite caregivers to the platform to view their medical history and help them in their care journey.
Patients can also share their information with their providers.
The provider side of the mobile app allows the doctor to view the patient’s longitudinal case summary as well as any PROs, manage patient encounters and includes a chat function for the patient’s medical team to communicate with each other regarding the patient’s case.
Conclusion: We demonstrate that it is possible to build and deploy a mobile application to support patient-provider engagement.
We show initial results that are promising for a bi-directional platform that reduces friction in patient-provider engagement.
Citation Format: Sharon Hensley Alford, Rohit Mahatma, Sagar Amode, Rupal Sethia, Kartik Mahatma, Hitesh Mahatma, Varun Mahatma, Nayan Sonawane, Shilpa Mahatma, Tarun Kumar, Kanchan Chawala.
Development of technology for bi-directional, tailored support of the relationship between breast cancer patients and their providers [abstract].
In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX.
Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-12-03.
Related Results
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Coexisting Granulomatous Mastitis and Breast Cancer: A Systematic Review
Coexisting Granulomatous Mastitis and Breast Cancer: A Systematic Review
Abstract
Introduction: Granulomatous mastitis (GM) is a rare inflammatory breast disease that mimics carcinoma. GM can coexist with breast cancer (BC), though the relationship rema...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Desmoid-Type Fibromatosis of The Breast: A Case Series
Desmoid-Type Fibromatosis of The Breast: A Case Series
Abstract
IntroductionDesmoid-type fibromatosis (DTF), also called aggressive fibromatosis, is a rare, benign, locally aggressive condition. Mammary DTF originates from fibroblasts ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...

